SUPN Delivers Robust Q3 with 52% Growth from Core Products, Sage Acquisition, and Upbeat Guidance

Four Growth Products Drive a 52% Revenue Surge

Supernus Pharmaceuticals (NASDAQ: SUPN) announced its third quarter 2025 results, headlined by an impressive 52% year-over-year growth in combined revenues from its four key growth products: Qelbree®, GOCOVRI®, ZURZUVAE®, and ONAPGO™. Total revenues for the quarter rose 9% to $192.1 million, with these four products contributing $149.2 million—highlighting management's focus on high-growth CNS therapeutics as older legacy brands face generic pressure.

This outsized growth was further fueled by the acquisition of Sage Therapeutics in late July, contributing proportionate collaboration revenue from ZURZUVAE (U.S. sales of ZURZUVAE as reported by Biogen jumped 150% year-over-year and 19% sequentially).

ONAPGO Launches Strong but Faces Temporary Supply Constraints

ONAPGO, the first and only subcutaneous apomorphine infusion device for advanced Parkinson's motor fluctuations, posted a solid $6.8 million in its first full commercial quarter post-launch. More than 1,300 patient enrollments and strong physician interest underscore market demand. However, supply chain constraints have temporarily capped new patient initiations, with Supernus focusing on uninterrupted care for current patients while ramping up production. Investors will want to watch how quickly the company resolves this issue, given the product's outsized growth potential.

Qelbree Prescriptions Hit New High, ZURZUVAE Collaboration Accelerates

Qelbree, Supernus’ ADHD medication, delivered $81.4 million in net sales—up 31% from Q3 2024—and set a new prescription record with 238,770 fills for the quarter. Collaboration revenue from ZURZUVAE came in at $20.2 million (covering just two months), with Biogen reporting a sharp sales uptick, suggesting positive market uptake for postpartum depression therapy. GOCOVRI net sales also climbed 15%, continuing its upward trajectory in prescriptions and physician adoption.

Legacy Brands Decline, But Newer Products Offset Generic Erosion

Older products like APOKYN®, Trokendi XR, and Oxtellar XR saw substantial declines in sales due to ongoing generic competition, with Oxtellar XR dropping 59%. Still, when excluding these brands, non-GAAP revenues rose a strong 30% to $170 million for the quarter, confirming that the growth products are now the engine of Supernus' commercial story.

Acquisition and Pipeline Bolster Long-Term Strategy

The Sage Therapeutics acquisition brought in new collaboration revenue and a more diversified pipeline, while the ONAPGO and ZURZUVAE launches suggest that recent R&D and commercial bets are bearing fruit. Clinical pipeline advances include a Phase 2b study for SPN-817 in epilepsy, an upcoming Phase 2b trial for SPN-820 in major depressive disorder, and a planned Phase 1 trial for SPN-443 targeting ADHD in 2026.

Operating Losses Driven by One-Time Charges, But Guidance Raised

Despite these revenue gains, Supernus posted an operating loss of $60.2 million for Q3 (compared to a $40.9 million profit in Q3 2024), primarily due to one-off expenses tied to the Sage deal and intangible amortization. Adjusted non-GAAP operating earnings, which strip out these costs, were $41.9 million for the quarter, though below last year's level. Cash reserves were solid at $281.2 million at quarter-end after funding the Sage purchase.

The company lifted its full-year 2025 total revenue guidance to a range of $685-$705 million (from a prior $670-$700 million), and adjusted operating earnings to $125-$145 million (from $105-$135 million), signaling confidence in execution and pipeline momentum—even as SG&A and integration costs remain elevated.

Investor Takeaway: Focus Shifts to Execution, Supply Chain, and New Indications

Supernus has emerged from Q3 2025 as a high-growth CNS specialty pharma, with successful new product launches countering erosion in legacy franchises. With supply resolution on ONAPGO and ongoing strength in Qelbree and ZURZUVAE, management sees a path to sustained revenue growth and long-term shareholder value creation. Still, operating margin expansion will require successful integration, cost management, and scaling the company’s new portfolio as the post-acquisition dust settles. The market’s attention will now shift to supply chain recovery, pipeline trial results, and the pace of integration synergies in 2026.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI